iTeos Therapeutics is a pioneering biopharmaceutical company based in Watertown, MA, specializing in the discovery and development of highly differentiated immuno-oncology therapeutics for cancer patients. With a deep understanding of the tumor microenvironment and immunosuppressive pathways, iTeos designs novel targeted immunotherapies to improve the clinical benefit of oncology therapies.
The company's dynamic pipeline includes two clinical stage programs, EOS-448 and Inupadenant, which are rapidly advancing into late-stage clinical trials to explore their full potential. iTeos is committed to corporate responsibility and incorporates Environmental, Social, and Governance (ESG) principles into its operations to create sustainable value for society and stakeholders.
Generated from the website